Public Meeting on Patient-Focused Drug Development

October 25, 2012

8:30 – 9:00 am	**Registration**
9:00 – 9:05 am	**Welcome** Patrick Frey *Director, Office of Planning and Analysis, FDA*
9:05 – 9:15 am	**Opening Remarks** Janet Woodcock, MD *Director, Center for Drug Evaluation and Research, FDA*
9:15 – 9:30 am	**Patient-Focused Drug Development Overview** Theresa Mullin, PhD *Director, Office of Planning and Informatics, FDA*
9:30 – 10:00 am	**Panel: FDA Perspectives** John Jenkins, MD *Director, Office of New Drugs* Donna Griebel, MD *Director, Division of Gastroenterology and Inborn Errors Products* Patricia Keegan, MD *Director, Division of Oncology Products II* Theresa Michele, MD *Team Lead, Division of Pulmonary, Allergy, and Rheumatology Products* Ginette Michaud, MD *Deputy Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research*
10:00 – 10:15 am	**Break**
10:15 – 11:15 am	**Open Public Comment: Disease Area Nominations**
11:15 – 11:45 am	**Panel: Incorporating Patient Perspectives** Anne Pariser, MD *Associate Director for Rare Diseases, Office of New Drugs, FDA* Megan O'Boyle *Patient Advocate, Phelan-McDermid Syndrome Foundation* Jason Lundy, PhD *Assistant Director, Patient-Reported Outcome Consortium, Critical Path Institute*
11:45 am – 12:15 pm	**Open Public Comment: Incorporating Patient Perspectives**
12:15 – 12:30 pm	**Wrap Up**